Gefapixant

Drug Profile

Gefapixant

Alternative Names: AF-219; MK-7264; R1646; RG-1646; RO 4926219

Latest Information Update: 06 Jun 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Merck & Co; Roche
  • Class Analgesics; Small molecules
  • Mechanism of Action Purinergic P2X3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Asthma; Cough; Interstitial cystitis; Musculoskeletal pain
  • Discontinued Overactive bladder; Pain

Most Recent Events

  • 22 May 2017 Safety and efficacy data from a phase II trial in Cough released by Merck
  • 14 Apr 2017 Merck initiates enrolment in a phase I pharmacokinetic trial (In adults, In the elderly) in USA (PO) (NCT03108924)
  • 06 Apr 2017 Merck Sharp & Dohme Corp. plans a phase I trial for Renal failure in USA (NCT03108924)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top